8-K filing — IRIDEX CORP (IRIX)
Filed: 2026-09-02 AccNo: 0001193125-26-380229 Size: 173 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Iridex Q2 EPS $(0.07) Misses $(0.01) Estimate, Sales $12.566M Miss $13.587M Estimate
Iridex (NASDAQ:IRIX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.01) by 600 percent. This is a 16.67 percent decrease over losses of $(0.06) per share from the same
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Iridex shares are trading lower after the company reported worse-than-expected Q2 financial results.
Full Transcript: Iridex Q2 2026 Earnings Call
Iridex (NASDAQ:IRIX) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data.
Iridex Affirms FY2026 Sales Guidance of $51.000M-$53.000M vs $53.227M Est
Iridex (NASDAQ:IRIX) affirms FY2026 sales outlook from $51.000 million-$53.000 million to $51.000 million-$53.000 million vs $53.227 million estimate.